Johnson & Johnson (NYSE:JNJ) has stalled development of lumicitabine (AL-8176), an antiviral candidate that was a key to its $1.75 billion acquisition of Alios BioPharma Inc. in 2014, and revealed a resulting impairment charge of about $630 million in its 3Q18 earnings.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,